Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma

Inclusion Criteria: Life expectancy more than three months diagnosed with multiple myeloma (MM) relapsed following a response to any conventional MM therapy, and refractory to their most recent MM therapy Karnofsky performance status = 60 no electrocardiographic evidence of acute ischemia or new conduction system abnormalities no history of myocardial infarction within last 6 months serum concentrations of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3X upper limit of normal (ULN) total serum bilirubin = 2X ULN Calculated or measured creatinine clearance >30 mL/min platelet count = 30 x 10(9)/L hemoglobin concentration = 8 g/dL white blood cell count = 2.0 x 10(9)/L Exclusion Criteria: Patients with non-secretory myeloma, plasma cell leukemia, or POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes) major surgery within four weeks of enrollment severe elevated serum calcium heart failure receipt of chemotherapy within 21 days before enrollment, receiving immunotherapy, radiation therapy, or other investigational agents receipt of corticosteroids equivalent to more than 10 mg/day of prednisone within two weeks before enrollment known allergies to agents used in bortezomib (e.g., boron or mannitol) poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol